<div id="readability-page-1"><p>Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report)'s share price traded down 3.7% on Thursday following insider selling activity. The stock traded as low as $530.96 and last traded at $554.93. 157,218 shares traded hands during trading, a decline of 61% from the average session volume of 408,083 shares. The stock had previously closed at $576.49.</p><ul><li>Can Medpace Stock Keep up this Pace?</li></ul><p>Specifically,  CEO August J. Troendle sold 23,178 shares of the company's stock in a transaction on Monday, December 1st. The shares were sold at an average price of $593.25, for a total value of $13,750,348.50. Following the completion of the sale, the chief executive officer owned 652,550 shares in the company, valued at $387,125,287.50. This represents a 3.43% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through the SEC website. Also, CEO August J. Troendle sold 15,151 shares of Medpace stock in a transaction on Friday, November 28th. The shares were sold at an average price of $593.46, for a total transaction of $8,991,512.46. Following the completion of the transaction, the chief executive officer owned 675,728 shares in the company, valued at approximately $401,017,538.88. This represents a 2.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In other news, CEO August J. Troendle sold 41,331 shares of the stock in a transaction dated Wednesday, November 26th. The shares were sold at an average price of $606.88, for a total transaction of $25,082,957.28. Following the completion of the sale, the chief executive officer owned 690,879 shares in the company, valued at approximately $419,280,647.52. This represents a 5.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this link. </p><h2>Analysts Set New Price Targets</h2><p>Several equities analysts recently issued reports on the company. Truist Financial  set a $555.00 price target on Medpace in a research report on Monday, October 27th. Cowen  reissued a &#34;sell&#34; rating on shares of Medpace in a report on Friday, October 24th. Mizuho increased their price target on Medpace from $575.00 to $655.00 and gave the stock an &#34;outperform&#34; rating in a report on Friday, October 24th. BMO Capital Markets assumed coverage on shares of Medpace in a research report on Thursday, November 13th. They issued a &#34;market perform&#34; rating and a $600.00 price objective on the stock. Finally, Jefferies Financial Group upped their price objective on shares of Medpace from $400.00 to $450.00 and gave the stock a &#34;hold&#34; rating in a research report on Tuesday, September 9th. One investment analyst  has rated the stock with a Strong Buy rating, two have issued  a Buy rating, ten have issued  a Hold rating and four have assigned  a Sell rating to the company. Based on data from MarketBeat, the stock  has a consensus rating of &#34;Hold&#34; and an average price target of $487.18.</p><p><b>View Our Latest Stock Report on MEDP</b></p><h2>Medpace Trading Down 3.7%</h2><p>The firm has a market capitalization of $15.63 billion, a price-to-earnings ratio of 38.81, a PEG ratio of 2.21 and a beta of 1.43. The stock's 50 day moving average price is $565.74 and its two-hundred day moving average price is $450.35. </p><p>Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, beating the consensus estimate of $3.50 by $0.36. The firm had revenue of $659.90 million during the quarter, compared to analysts' expectations of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The business's revenue for the quarter was up 23.7% compared to the same quarter last year. During the same quarter last year, the business earned $3.01 earnings per share. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS.  On average, sell-side analysts forecast that  Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year. </p><h2>Institutional Trading of Medpace</h2><p>Several large investors have recently modified their holdings of the business. Quent Capital LLC acquired a new stake in shares of  Medpace during the 3rd quarter worth about $25,000.  Optiver Holding B.V. purchased a new position in shares of  Medpace during the third quarter valued at approximately $27,000.  Quarry LP acquired a new stake in  Medpace during the third quarter worth approximately $35,000.  Root Financial Partners LLC purchased a new stake in  Medpace in the 3rd quarter worth approximately $38,000.  Finally, Geneos Wealth Management Inc. raised its holdings in  Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock valued at $29,000 after acquiring an additional 37 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Medpace Company Profile</h2> (Get Free Report)<p>Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.</p><h2>See Also</h2><ul><li>Five stocks we like better than Medpace</li><li>Uptrend Stocks Explained: Learn How to Trade Using Uptrends</li><li>Can Alibaba’s Big Bets Pay Off After a Breakout Year?</li><li>What is a SEC Filing?</li><li>How Accenture's OpenAI Partnership Turns AI Hype Into Profits</li><li>What is a Death Cross in Stocks?</li><li>Battle of the Big-Upside Tech Names: HUBS vs. NBIS vs. TEAM</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Medpace Right Now?</h2><p>Before you consider Medpace, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.</p><p>While Medpace currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

MEDP

<p>Medpace's stock price fell by 3.7% following insider selling by CEO August J. Troendle, who sold significant shares over several transactions. The stock traded as low as $530.96, with a notable decrease in trading volume. Analysts have mixed ratings on the stock, with a consensus 'Hold' rating and an average price target of $487.18. Medpace reported strong quarterly earnings, beating estimates, and has set its FY 2025 guidance at 14.600-14.860 EPS.</p>

Medpace (NASDAQ:MEDP) Stock Price Down 3.7% After Insider Selling